Generic Medicine Info
Hypersensitivity to E. coli-derived proteins or anakinra. Neutropenia (absolute neutrophil count <1.5 x 109/L). Severe renal impairment (CrCl <30 mL/min).
Special Precautions
Patient w/ active infections, including chronic or localised infections, history of recurrent infections or w/ underlying conditions that may predispose to infections, asthma. Moderate renal (CrCl 30-50 mL/min) and severe hepatic impairment. Pregnancy and lactation. Monitoring Parameters Monitor neutrophil counts before initiating treatment, mthly during the 1st 6 mth, and quarterly thereafter.
Adverse Reactions
Infection (e.g. upper resp tract infection, sinus infection), mild to moderate inj site reactions w/ symptoms of erythema, bruising, swelling and pain, headache, nausea, diarrhoea, abdominal pain, elevated transaminases, non-infectious hepatitis. Rarely, allergic reactions e.g. rashes.
Drug Interactions
Enhanced adverse effects of live vaccines. Co-admin w/ etanercept or other tumour necrosis factor (TNF) inhibitors may induce serious infection and neutropenia.
ATC Classification
L04AC03 - anakinra ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.
Disclaimer: This information is independently developed by CIMS based on anakinra from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in